1101PHEALTHCARE RESOURCE UTILIZATION (HCRU) IN PATIENTS RECEIVING IPILIMUMAB FOR ADVANCED MELANOMA: IMPACT OF SURVIVAL AND EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) STATUS

ABSTRACT Aim: A recent large pooled survival analysis has shown that ipilimumab (ipi) conveys long-term survival benefit in a significant proportion of patients (pts) with advanced melanoma (mel). We conducted a retrospective study of clinical outcomes and adverse events (AEs) among pts receiving ipi in a real world setting which may define whether longer survival is associated with increased HCRU. The present analysis describes HCRU by length of survival and baseline ECOG status. Methods: This medical chart review comprised adult pts in the US with unresectable stage III/IV mel treated in a community setting with ≥1 dose of ipi 3 mg/kg as first-line monotherapy between 04/2011 and 09/2012. Demographic/clinical characteristics, details of ipi dosing and subsequent therapies, AEs, and HCRU (hospitalizations, emergency department (ED) visits, nursing home stays) were collected. Pts were categorized according to survival ( Results: Data were abstracted from 273 pt charts at 34 sites. As of 12/20/2013, 231 pts had been followed ≥1 year or until death, and 200 had ECOG status recorded. The 4 groups were similar in age (median 64 years), sex (66% male), and race (95% white). More hospitalizations per pt occurred among pts surviving Conclusions: In this population, the rate of resource use was lower among those surviving ≥1 year than among those surviving Healthcare Resource Utilization during Follow-Up, Mean (SD) Survived ≥1 year ECOG 0 N = 55 Survived ≥1 year ECOG ≥1 N = 51 Survived ECOG 0 N = 26 Survived ECOG ≥1 N = 68 Hospitalizations Number per pt per 100 days* Total days per pt per 100 days * 0.08 (0.16) 0.49 (1.17) 0.09 (0.19) 0.35 (0.79) 0.50 (0.70) 2.22 (3.45) 1.13 (1.77) 5.12 (8.93) Emergency department visits, number per pt per 100 days 0.01 (0.05) 0.02 (0.11) 0 (0) 0.02 (0.07) Nursing home stays Pts (%) Total days per pt per 100 days 1.8% 0.04 (0.30) 5.9% 0.46 (2.01) 7.7% 1.63 (7.20) 7.4% 1.89 (9.00) * p Disclosure: A. Tarhini: Advisory boards: Bristol-Myers Squibb, Merck, and Genentech; Corporate-sponsored research: Bristol-Myers Squibb, Merck, Novartis, Amgen, and Prometheus. A.S. Rao: Employee of Bristol-Myers Squibb. S. Corman: Employee of Pharmerit International; consulting fee or honorarium paid by Bristol-Myers Squibb to Pharmerit International. M. Botteman: employee of Pharmerit International; consulting fee from Bristol-Myers Squibb during the conduct of the study. S. Mehta: employee of Pharmerit International; consulting fee or honorarium paid by Bristol-Myers Squibb to Pharmerit International. X. Ji: employee of Pharmerit International; consulting fee or honorarium paid by Bristol-Myers Squibb to Pharmerit International. M. Katyal: Employee of Medical Data Analytics; corporate-sponsored research: Medical Data Analytics is consultant vendor to Bristol-Myers Squibb, Inc., the financial sponsor of this research study. K. Margolin: Corporate-sponsored research: GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Pfizer, Altor, and Prometheus.